Research goals
High-level goals steer the foundry over weeks. You set them, the daily scan sets them autonomously, and self-correction proposes new ones for you to approve.
Validate IKZF1 as a druggable microglial checkpoint regulator that integrates amyloid clearance dynamics with TREM2-independent inflammatory states, prioritizing pharmacogenetic stratification by IKZF1 variants and TREM2 status.
PMID:42858065 nominates IKZF1 as an AD microglial regulator through single-cell gene networks, representing a novel therapeutic axis orthogonal to our TREM2-focused insights. This aligns with strategy memory requiring independent mechanistic replication and genetic stratification. IKZF1 (Ikaros) is druggable via existing immunomodulators (lenalidomide, iberdomide) with known safety profiles, reducing hepatotoxicity/cardiovascular risks that plagued prior hypotheses. PMID:42858060 reframes plasma Aβ variability as measurable clearance signal rather than noise, providing a pharmacodynamic biomarker for IKZF1-targeted microglial modulation. The cell-type specificity addresses our gap in subtype-selective interventions, while PMID:42840584's network medicine foundation models enable predictive genotype-treatment interaction modeling before clinical deployment. No active goals exist, and this mechanistically complements our TREM2 pathway knowledge without duplicating inflammatory-only approaches.